Drugs / JNJ-39588146
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01120210 | Jun 2010 → Sep 2011 | heart failure | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Mixed |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-39588146 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01120210 ↗ |
| Known as | human stresscopin acetate | “We examined the safety, pharmacokinetics, and effects on haemodynamics and serum biomarkers of intravenous human stresscopin acetate (JNJ-39588146) in patients with stable HF...” PMID 23471413 ↗ Mar 2013 |
| Route | Intravenous | “intravenous human stresscopin acetate (JNJ-39588146)” PMID 23471413 ↗ Mar 2013 |